GH * 주식 개요 는 정밀 종양학 회사로 미국과 전 세계에서 혈액 및 조직 검사, 데이터 세트, 분석을 제공합니다. 자세한 내용
생각, 링크 및 회사 내러티브를 캡처하세요.
Guardant Health, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Guardant Health 과거 주가 현재 주가 US$731.50 52주 최고치 US$731.50 52주 최저치 US$293.83 베타 1.28 1개월 변경 0% 3개월 변경 사항 n/a 1년 변경 사항 n/a 3년 변화 -58.39% 5년 변화 -52.19% IPO 이후 변화 -53.50%
최근 뉴스 및 업데이트
Chief Information Officer recently sold Mex$4.2m worth of stock Nov 22
Lead Independent Director recently sold Mex$4.4m worth of stock Nov 15
Third quarter 2024 earnings released: US$0.88 loss per share (vs US$0.73 loss in 3Q 2023) Nov 08
Guardant Health, Inc. Revises Revenue Guidance for the Year 2024 Nov 07
Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director Oct 25
Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 16 더 많은 업데이트 보기
Chief Information Officer recently sold Mex$4.2m worth of stock Nov 22
Lead Independent Director recently sold Mex$4.4m worth of stock Nov 15
Third quarter 2024 earnings released: US$0.88 loss per share (vs US$0.73 loss in 3Q 2023) Nov 08
Guardant Health, Inc. Revises Revenue Guidance for the Year 2024 Nov 07
Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director Oct 25
Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 16 Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million. Aug 24
Second quarter 2024 earnings released: US$0.84 loss per share (vs US$0.67 loss in 2Q 2023) Aug 09
Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024 Aug 08
Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer Aug 02
High number of new directors Aug 01
Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 25
Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance Jul 23
Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors Jul 19
Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer Jun 05 Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
First quarter 2024 earnings released: US$0.94 loss per share (vs US$1.30 loss in 1Q 2023) May 11
Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024 May 11
Guardant Health, Inc., Annual General Meeting, Jun 12, 2024 Apr 28
Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024 Apr 20
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting Apr 03
Chief Information Officer recently bought Mex$656k worth of stock Mar 26
Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer Mar 14
Full year 2023 earnings released: US$4.28 loss per share (vs US$6.41 loss in FY 2022) Feb 24
Guardant Health, Inc. Provides Earnings Guidance for the Year 2024 Feb 23 Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024
Guardant Health, Inc. Announces Executive Changes Jan 02
Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test Dec 20
Guardant Health, Inc. to Appeal Federal District Court Verdict Nov 17
Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023 Nov 07
Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial Oct 24
Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Oct 17
Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan Sep 07
Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations Sep 06
Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023 Aug 04
Second quarter 2023 earnings released: US$0.67 loss per share (vs US$2.25 loss in 2Q 2022) Aug 04
Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research Aug 03
Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Jul 13 Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan Jul 06
Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index Jun 25
High number of new directors Jun 16 Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million. May 24
First quarter 2023 earnings released: US$1.30 loss per share (vs US$1.21 loss in 1Q 2022) May 12
High number of new directors May 12
Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023 May 11
Guardant Health, Inc. Announces Management Changes May 09
High number of new directors Apr 25
Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer Feb 16
Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer Feb 09
Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 02
Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery Feb 01
Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer Jan 31
Guardant Health and the Royal Marsden NHS Foundation Trust Partner on Highly Anticipated TRACC Part C Trial to Use Guardant Reveal(Tm) Blood Test to Help Guide Treatment Decisions in Colorectal Cancer Jan 21
Guardant Health, Inc. to Showcase New Data at ASCO GI 2023 Demonstrating Utility of its Blood Tests for Patients with Gastrointestinal Cancers Jan 18
Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 11
Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 Jan 10
Guardant Health, Inc. and Susan G. Komen(R) Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit from Additional Monitoring or Therapy Dec 22
Guardant Health Announces Positive Results from Pivotal ECLIPSE Study Evaluating A Blood Test for the Detection of Colorectal Cancer Dec 16
Chief Information Officer recently sold Mex$3.1m worth of stock Nov 18
Third quarter 2022 earnings released: US$1.58 loss per share (vs US$1.06 loss in 3Q 2021) Nov 05
Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022 Nov 04
Guardant Health, Inc. to Report Q3, 2022 Results on Nov 03, 2022 Oct 11
Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner Sep 10
Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Portfolio of Blood Tests for Advanced-Stage Cancer Patients Sep 07
Senior Vice President of People recently sold Mex$4.3m worth of stock Aug 16
Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Daiichi Sankyo and Astrazeneca’S Enhertu® for Treatment of Nsclc Patients with Activating Her2 Mutations Aug 13
Second quarter 2022 earnings released: US$2.25 loss per share (vs US$0.96 loss in 2Q 2021) Aug 05
Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022 Aug 05
Guardant Health, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 14
Guardant Health, Inc. Appoints Steve E. Krognes as Class III Director, Effective June 30, 2022 Jul 08
Guardant Health, Inc. Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-Of-Its Kind Prospective Study At Digestive Disease Week 2022 May 22
Guardant Health, Inc. Provides Revenue Guidance for the Year 2022 May 06
Guardant Health, Inc. Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults May 03
Guardant Health, Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 14
Guardant Health, Inc. Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting Apr 12
Guardant Health, Inc. Announces That Stanley Meresman Will Not Stand for Re-Election to the Company’s Board of Directors Mar 03
Guardant Health, Inc. Provides Revenue Guidance for the Year 2022 Feb 24
Guardant Health, Inc. to Report Q4, 2021 Results on Feb 23, 2022 Feb 02
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium Jan 20
Guardant Health, Inc. Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults Jan 19
Guardant Health Reaches Target Enrollment of 12,750 Patients in Eclipse Pivotal Study for Its Lunar-2 Blood Test to Detect Colorectal Cancer Dec 19
High number of new directors Dec 03
Guardant Health, Inc. Reaffirms Revenue Guidance for the Year 2021 Aug 08
TwinStrand Biosciences, Inc. Announces Filing of Patent Infringement Lawsuit against Guardant Health, Inc Aug 05
Guardant Health Expands Guardant360® Portfolio with New Tests for Treatment Response Monitoring and Complete Genomic Profiling Jun 23
Guardant Health, Inc. Presents Data At 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients with Early-Stage Cancer Jun 05
Guardant Health, Inc. Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer May 29
Guardant360 CDx Receives FDA Approval as Companion Diagnostic for Janssen’s RYBREVANT (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 22
Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2021 May 07
Full year 2020 earnings released: US$2.60 loss per share (vs US$0.83 loss in FY 2019) Feb 26
Revenue beats expectations Feb 26
Guardant Health, Inc. Launches Guardant Reveal™ Liquid Biopsy Test for Residual Disease and Recurrence Monitoring in Patients with Early-Stage Colorectal Cancer Feb 18 주주 수익률 GH * MX Healthcare MX 마켓 7D 0% 3.4% 1.2% 1Y n/a -30.7% -11.1%
전체 주주 수익률 보기
수익률 대 산업: MX Healthcare 산업에 대해 GH * 의 성과를 판단하기에는 데이터가 부족합니다.
수익률 대 시장: MX 시장에 대해 GH * 의 성과를 판단하기에는 데이터가 부족합니다.
가격 변동성 Is GH *'s price volatile compared to industry and market? GH * volatility GH * Average Weekly Movement n/a Healthcare Industry Average Movement 7.3% Market Average Movement 4.0% 10% most volatile stocks in MX Market 6.2% 10% least volatile stocks in MX Market 2.7%
안정적인 주가: GH * 의 주가는 지난 3개월 동안 MX 시장과 비교해 변동성이 컸습니다.
시간에 따른 변동성: 지난 1년간 GH * 의 변동성 변화를 확인하기에는 데이터가 충분하지 않습니다 .
회사 소개 정밀 종양학 회사인 가던트 헬스(Guardant Health, Inc.)는 미국 및 전 세계에 혈액 및 조직 검사, 데이터 세트, 분석 서비스를 제공합니다. 이 회사는 가던트360, 가던트360 LDT, 가던트360 CDx 테스트, 가던트360 반응 테스트, 가던트360 티슈넥스트 테스트, 가던트인피니티 테스트, 임상 및 바이오 제약 고객을 위해 설계된 통합 소프트웨어 기반 솔루션인 가던트커넥트, 분석 검사 환자를 잠재적으로 관련성이 있는 임상 연구와 연결하기 위한 가던트OMNI 테스트, 진행기 암을 위한 가던트OMNI, 다양한 바이오마커 기반의 종양 진화 및 치료 저항성 연구 플랫폼인 인실리카 인폼을 제공하고 있습니다. 또한 초기 암 환자의 보조 치료 선택을 위한 쉴드 테스트, 가던트 리빌 테스트, 스마트 액체 생검 플랫폼, 암 바이오마커 검출을 개선하는 인공지능 기반 디지털 병리 플랫폼인 가던트 갤럭시를 제공합니다.
자세히 보기 Guardant Health, Inc. 기본 사항 요약 Guardant Health 의 수익과 매출은 시가총액과 어떻게 비교하나요? GH * 기본 통계 시가총액 Mex$93.98b 수익(TTM ) -Mex$10.62b 수익(TTM ) Mex$14.35b
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) GH * 손익 계산서(TTM ) 수익 US$692.26m 수익 비용 US$274.72m 총 이익 US$417.53m 기타 비용 US$929.94m 수익 -US$512.41m
주당 순이익(EPS) -4.15 총 마진 60.31% 순이익 마진 -74.02% 부채/자본 비율 -1,900.1%
GH * 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2025/01/11 23:53 장 마감 주가 2024/12/02 00:00 수익 2024/09/30 연간 수익 2023/12/31
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Guardant Health, Inc. 30 애널리스트 중 22 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Michael Ryskin BofA Global Research Derik de Bruin BofA Global Research Mark Massaro BTIG
27 더 많은 분석가 보기 
